Compare Stitch Fix Inc (SFIX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs Viatris Inc — how do they compare? Stitch Fix Inc trades at $3.79 (market cap $497.68M), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 37.6× Stitch Fix Inc's market cap, and Viatris Inc pays a 2.95% dividend while Stitch Fix Inc pays none. Which is the better fit depends on your goals.
| SFIX | VTRS | |
|---|---|---|
Market Cap | $497.68M | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $5.83 | $17.86 |
52-Week Low | $3.06 | $9.49 |
Enterprise Value | $385.40M | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $3.97, down 5.48% today, as the online personal styling service shows mixed signals. While revenue has stabilized around $1.3B annually and losses are narrowing significantly, the company remains unprofitable with a -1.43% net margin. Technical indicators show a bullish trend with strong momentum signals, though oscillators remain neutral. Recent news highlights AI-driven personalization initiatives and active client growth as potential turnaround catalysts.
The stock presents a speculative recovery opportunity with improving fundamentals but carries execution risks. Analyst consensus is cautious with a $4.75 price target (20% upside) but only 27% buy ratings. Key risks include consumer spending pressure and the challenge of achieving sustainable profitability in the competitive retail sector.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
